>>> So, my question is:
>>> Do you have any advice (or could you provide examples on the
>>> piggy bank website) for how best to express bibliographic
>>> information/metadata in RDF linked from a web page?
>>> What do you think about the idea of using PRISM: http://
>>> www.prismstandard.org/resources/mod_prism.html
In HubMed I'm using RDF in this (example <
http://www.hubmed.org/
export/rdf.cgi?uids=16002735>) format:
<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
xmlns:bibtex="
http://purl.oclc.org/NET/nknouf/ns/bibtex#"
xmlns:rdf="
http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:dc="
http://purl.org/dc/elements/1.1/"
xmlns:prism="
http://prismstandard.org/namespaces/1.2/basic/"
xmlns:foaf="
http://xmlns.com/foaf/0.1/"
xmlns:vcard="
http://www.w3.org/2001/vcard-rdf/3.0#"
>
<bibtex:article rdf:about="uri:info:pmid/16002735">
<dc:title>Targeting Positive Regulatory Domain I-Binding Factor 1
and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-
Reactive CTL.</dc:title>
<dc:description>Growing evidence indicates that multiple myeloma
(MM) and other malignancies are susceptible to CTL-based immune
interventions. We studied whether transcription factors inherently
involved in the terminal differentiation of mature B lymphocytes into
malignant and nonmalignant plasma cells provide MM-associated CTL
epitopes. HLA-A*0201 (A2.1) transgenic mice were used to identify
A2.1-presented peptide Ag derived from the plasma cell-associated
transcriptional regulators, positive regulatory domain I-binding
factor 1 (PRDI-BF1) and X box-binding protein 1 (XBP-1). A2.1-
restricted CTL specific for PRDI-BF1 and XBP-1 epitopes efficiently
killed a variety of MM targets. PRDI-BF1- and XBP-1-reactive CTL were
able to recognize primary MM cells from A2.1(+) patients. Consistent
with the expression pattern of both transcription factors beyond
malignant and nonmalignant plasma cells, PRDI-BF1- and XBP-1-specific
CTL activity was not entirely limited to MM targets, but was also
associated with lysis of certain other malignancies and, in defined
instances, with low-to-intermediate level recognition of a few types
of normal cells. Our results also indicate that the A2.1-restricted,
PRDI-BF1- and XBP-1-specific human CD8(+) T cell repertoire is
affected by partial self tolerance and may thus require the transfer
of high-affinity TCR to break tolerance. We conclude that
transcription factors governing terminal cellular differentiation may
provide MM- and tumor-associated CTL epitopes.</dc:description>
<dc:creator>
<foaf:Person>
<foaf:name>C Lotz</foaf:name>
<vcard:Given></vcard:Given>
<vcard:Family>Lotz</vcard:Family>
</foaf:Person>
</dc:creator>
...
<dc:creator>
<foaf:Person>
<foaf:name>M Theobald</foaf:name>
<vcard:Given></vcard:Given>
<vcard:Family>Theobald</vcard:Family>
</foaf:Person>
</dc:creator>
<dc:identifier></dc:identifier>
<prism:publicationName>J Immunol</prism:publicationName>
<prism:publicationDate>2005-07-15</prism:publicationDate>
<prism:volume>175</prism:volume>
<prism:number>2</prism:number>
<prism:startingPage>1301</prism:startingPage>
<prism:endingPage>1309</prism:endingPage>
<prism:isPartOf rdf:resource="urn:issn:0022-1767"/>
</bibtex:article>
</rdf:RDF>
linked with <link rel="alternate"...> in the head of each page, eg <
http://www.hubmed.org/display.cgi?uids=16002735>
dc:identifier contains something like 'doi:10.1038/nature03832', when
the DOI is available, and vcard:Given contains the author's first
name, when available.
Any suggestions for changes or additional data would be appreciated
(I don't have any citation data to add, unfortunately). I've been
thinking that dcterms:abstract might be a better fit than
dc:description.
alf.
Received on Wed Jul 13 2005 - 21:18:19 EDT